MTOR and triple-negative breast carcinoma: To determine whether mTOR inhibition increases populations of stem-like cells in established heterogeneous tumors, we treated mice harboring a triple-negative breast cancer patient-derived xenograft (PDX401) with INK128 (30 mg/kg, every second day for 2 weeks starting when tumors reached 5 mm in diameter).